GLPwatch

Saxenda vs Wegovy

Drug comparison

Last updated 2026-05-28 15:46 UTC

Saxenda (liraglutide) and Wegovy (semaglutide) are both injectable prescription medications made by Novo Nordisk for treating obesity. Saxenda is approved solely for weight management, while Wegovy is also approved to reduce cardiovascular risk in people with obesity. Both are given as once-daily shots under the skin, but they contain different active ingredients.

AI summary of the sources below.

Saxenda Wegovy
Active ingredientliraglutidesemaglutide
Manufacturernovo-nordisknovo-nordisk
Routesubcutaneous injectionsubcutaneous injection
FDA-approved forobesityobesity, cardiovascular risk reduction
Label updated2026-02-252026-05-05

Compare full details on the Saxenda and Wegovy pages.